Skip to main content

Table 3 TGF-β1 levels and baseline characteristics according to two groups determined by a TGF-β1 trajectory analysis

From: Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer

  n Group 1 n Group 2 p
TGF-β1 before RT (ng/ml) Md (IQR) 19 25.6 (22.3–28.6) 44 17.8 (15.9–19.9) < 0.001
TGF-β1 after RT (ng/ml), Md (IQR) 19 23.9 (21.3–25.2) 44 16.3 (13.7–19.1) < 0.001
TGF-β1 at 3 years (ng/ml), Md (IQR) 19 22.4 (18.8–25.8) 44 15.0 (12.1–18.8) < 0.001
Age, Md (IQR) 19 64 (58–66) 44 64 (59–68) 0.752
BMI, Md (IQR) 19 26.9 (24.8–32.3) 44 25.7 (24.1–28.7) 0.110
Left-sided BC, n (%) 19 14 (73.7) 44 36 (81.8) 0.508
AI-use, n (%) 19 6 (31.2) 44 15 (34.1) 1.000
Tamoxifen use, n (%) 19 2 (10.5) 44 4 (9.1) 1.000
ACE or ARB use, n (%) 19 5 (26.3) 44 12 (27.3) 1.000
ASA use, n (%) 19 1 (5.3) 44 4 (9.1) 1.000
Beta-blocker use, n (%) 19 4 (21.1) 44 7 (15.9) 0.721
Statin use, n (%) 19 3 (15.8) 44 10 (22.7) 0.738
CAD, n (%) 19 2 (10.5) 44 1 (2.3) 0.214
Diabetes, n (%) 17 3 (17.6) 42 2 (4.8) 0.138
Hypertension, n (%) 19 9 (47.4) 44 15 (34.1) 0.400
Hypothyroidism, n (%) 19 3 (15.8) 44 7 (15.9) 1.000
Smoking, n (%) 19 2 (10.5) 44 5 (11.4) 1.000
  1. TGF-β1 Transforming growth factor beta 1, RT Radiotherapy, Md Median, IQR Interquartile range, BMI Body mass index, BC Breast cancer, AI Aromatase inhibitor, ACE Angiotensin converting enzyme inhibitor, ARB Angiotensin II receptor blocker, ASA Low dose acetylsalicylic acid, CAD Coronary artery disease, Diabetes Use of diabetes medication